Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP cost of sales by Quarter
Non-GAAP cost of sales ($M) ($M)
Vertex Pharmaceuticals Non-GAAP cost of sales: $480M in Q2 2026, up 20.1% from a year earlier. That is the highest of the 38 quarters on record here.
Where the Q2 2026 figure comes from
“|| Non-GAAP cost of sales | $ | 480.3 | $ | 399.9 | $ | 864.9 | $ | 755.3”
Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP cost of sales ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-cogs
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.